- Rally Drives Best Day for Stocks This Quarter
- Congress Gets Obama Hedge Fund Disclosure Bill
- How China Is Behind Almost Every US Market Positive
- Porn at Work: How to Recognize a Sex Addict
- Slideshow: Leading US States for Porn Consumption
- Madoff's Former Accountant Close to Guilty Plea
- Goldman Analyst, Others Accused of Insider Trading
- The De-Construction of Steve Jobs' Mansion
- Fed: Economy Improving But Joblesses May Pass 10%
- Stock Picker: Use Dips to Strengthen Your Portfolio (Pt. 2)
- Stock Picker: Use Dips to Strengthen Your Portfolio (Pt. 1)
- Harry Potter's Magic Touch
- Biggest 3-day Gain for S&P Since Rally Started
- Apple Smacks Palm, and Palm's Hollow Plea
- Your Best Commodity Trades: Strategist
- Henes: There’s Gold in Them Hills - Private Equity and Distressed Investing
- My ICAD Infraction: One Year Later
- The De-Construction of Steve Jobs' Mansion
- Panama canal contract goes to Spanish-led team
- New Zealand's inflation rate drops to 1.9 percent
- Report: Toyota, Mazda to form tie-up on hybrids
- Hedge fund manager linked to Petters ordered freed
- Las Vegas Sands promotes executive Goldstein
- Documents: Boeing worried about aging work force
- Microsoft plans stores 'right next door to Apple'
- Senator holds up EPA nominee over climate study
- Mich. AG opposes Dems' bill on legal settlements
NEW YORK - GlaxoSmithKline PLC said Thursday it bought Bristol-Myers Squibb Co.'s branded generic business in Lebanon, Jordan, Syria, Libya and Yemen for about $23.2 million in cash.
The portfolio of products includes 13 drugs, with combined annual sales of $11.8 million in 2008. GlaxoSmithKline had revenue of $36.26 billion in 2008.
"This purchase is another step forward in GlaxoSmithKline's strategy to accelerate growth in emerging markets and signals a strong commitment to provide quality medicines to patients in the Middle East and North Africa," the company said in a statement.
The company said the move is part of an ongoing push into emerging markets. It previously bought similar products from Bristol-Myers in Pakistan and Egypt.
Shares of U.K.-based GlaxoSmithKline fell $1.19, or 3.3 percent, to close at $34.85 in a broadly lower market while shares of New York-based Bristol-Myers fell 47 cents, or 2.3 percent, to close at $19.77.



